Human Patents (Class 530/388.15)
-
Publication number: 20140127131Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).Type: ApplicationFiled: October 8, 2013Publication date: May 8, 2014Inventors: ROBIN BARBOUR, KATE DORA GAMES THIEL, TARLOCHAN S. NIJJAR
-
Patent number: 8715669Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.Type: GrantFiled: December 28, 2011Date of Patent: May 6, 2014Assignee: Novimmune SAInventors: Krzysztof Masternak, Olivier Leger
-
Patent number: 8715670Abstract: The present invention relates to a human monoclonal antibody that specifically binds to VCAM-1, and a therapeutic composition for the treatment of inflammatory disease or cancer comprising the same. The human monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human or mouse endothelial cell, effectively inhibits leukocyte adhesion to activated endothelial cells expressing VCAM-1, and shows a low immunogenicity, thereby being used for the treatment of cancer or inflammatory disease such as asthma, rhinitis, arthritis, multiple sclerosis, bowel disease, arteriosclerosis, myocardial infarction and transplant rejection.Type: GrantFiled: March 31, 2010Date of Patent: May 6, 2014Assignee: Hanwha Chemical CorporationInventors: Jung Tae Lee, Kyung Duk Moon, Ji Yong Yoon, Byung Je Sung, Dong Heon Lee, Il Sun Lee, Dong Eun Lee, Su Yeon Ryu, Young Woo Park, So Young Choi, Ji Hyun Park, Myeoung Hee Jang
-
Methods for treating conditions mediated by the inflammatory cytokine cascade using GAPDH inhibitors
Patent number: 8715658Abstract: The present invention is directed to a method of treating a subject at risk for or having a condition mediated by an inflammatory cytokine cascade comprising administering to the subject an amount of a GAPDH inhibitor effective to treat the subject at risk for or having a condition mediated by an inflammatory cytokine cascade.Type: GrantFiled: August 17, 2010Date of Patent: May 6, 2014Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin Tracey, William Parrish -
Patent number: 8715941Abstract: Anti-LRP6 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. These anti-LRP6 antibodies can be used to enhance Wnt activity and/or antagonize Dkk1 activity. Also described are methods of therapy using such antibodies and antigen-binding regions to bind modulate Wnt/LRP6 signaling to promote tissue homeostasis, regeneration and repair in diseases such as, but not limited to, bone disorders, such as osteoporosis, rheumatoid arthritis, and osteolytic lesions caused by osteoarthritis and multiple myeloma, gastrointestinal disease and wound healing.Type: GrantFiled: November 14, 2008Date of Patent: May 6, 2014Assignee: Arca Biopharma, Inc.Inventors: Arie Abo, Minke Binners
-
Patent number: 8715663Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.Type: GrantFiled: April 28, 2011Date of Patent: May 6, 2014Assignee: Amgen Inc.Inventors: Christopher J. Paszty, Hsieng Sen Lu
-
Patent number: 8715664Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.Type: GrantFiled: May 16, 2006Date of Patent: May 6, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Rebecca S. Hoffman, Mark Weinberg
-
Publication number: 20140120089Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: ApplicationFiled: December 19, 2013Publication date: May 1, 2014Applicants: PFIZER INC., AMGEN FREMONT INC.Inventors: Bruce D. Cohen, Jean Beebe, Jr., Penelope E. Miller, James D. Moyer, Jose Ramon Corvalan, Michael Gallo
-
Patent number: 8710191Abstract: Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, specifically human CCR2, and that may function to inhibit CCR2. Anti-CCR2 antibodies include those which bind to the first and/or second extracellular loops of CCR2. Also provided are human anti-CCR2 antibodies and antigen-binding portions thereof. Isolated heavy and light chain immunoglobulins derived from human anti-CCR2 antibodies and nucleic acid molecules encoding such immunoglobulins are provided. Methods of making human anti-CCR2 antibodies or antigen-binding portions, compositions comprising these antibodies or antigen-binding portions, methods of using the antibodies and antigen-binding portions, and compositions for diagnosis and treatment are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CCR2 antibodies or antigen binding portions thereof.Type: GrantFiled: August 17, 2009Date of Patent: April 29, 2014Assignees: Pfizer Inc., Amgen Fremont Inc.Inventors: Ronald P. Gladue, Bradley T. Keller, Shinji Ogawa, Arvind Rajpal, Laurie A. Tylaska, Shelley Sims Belouski, Larry L. Green, Meina Liang
-
Publication number: 20140115727Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor both in a ligand-dependent and in a ligand-independent manner, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: ApplicationFiled: August 29, 2013Publication date: April 24, 2014Applicant: Pierre Fabre MedicamentInventors: Liliane Goetsch, Thierry Wurch, Cedric Bes
-
Publication number: 20140105918Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.Type: ApplicationFiled: October 9, 2013Publication date: April 17, 2014Inventors: ROGER GOMIS, JOËL JEAN-MAIRET
-
Publication number: 20140105905Abstract: The present embodiments are related to high-affinity antibodies directed to IL-8, methods of making and characterizing such antibodies and uses of such antibodies. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided.Type: ApplicationFiled: November 20, 2013Publication date: April 17, 2014Applicant: Amgen Fremont, Inc.Inventors: John Babcook, Palaniswami Rathanaswami, Orit Foord, Jaspal S. Kang
-
Publication number: 20140099320Abstract: Described are human binding molecules specifically binding to enterococci and having killing activity against enterococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the molecules. The molecules can be used, for example, in the diagnosis, prophylaxis, and/or treatment of a condition resulting from Enterococcus.Type: ApplicationFiled: December 10, 2013Publication date: April 10, 2014Applicant: Crucell Holland B.V.Inventors: Mark Throsby, Robert A. Kramer, Cornelis A. de Kruif
-
Publication number: 20140093454Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: August 12, 2013Publication date: April 3, 2014Applicant: GENMAB A/SInventors: Jessica Teeling, Sigrid Ruuls, Martin Glennie, Jan G.J. van de Winkel, Paul Parren, Jørgen Petersen, Ole Baadsgaard, Haichun Huang
-
Patent number: 8685402Abstract: The invention relates to antibodies and antigen binding fragments thereof, that bind to hemagglutinin and neutralize infection of at least two different group 1 subtypes or at least two different group 2 subtypes of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.Type: GrantFiled: July 27, 2009Date of Patent: April 1, 2014Assignee: Institute for Research in BiomedicineInventor: Antonio Lanzavecchia
-
Patent number: 8679498Abstract: The present invention provides anti-N3pGlu A? antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the anti-N3pGlu A? antibodies or antigen-binding fragment thereof for the treatment of Alzheimers disease.Type: GrantFiled: August 9, 2011Date of Patent: March 25, 2014Assignee: Eli Lilly and CompanyInventors: Jirong Lu, Ying Tang, Ronald Bradley Demattos
-
Patent number: 8680247Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed.Type: GrantFiled: July 17, 2008Date of Patent: March 25, 2014Assignee: Medarex, L.L.C.Inventors: Jonathan Alexander Terrett, Li-Sheng Lu, Haichun Huang, Dapeng Yao, Chin Pan, Heidi Leblanc, Timothy Sproul, Mark Yamanaka
-
Patent number: 8673299Abstract: The invention relates to fully human monoclonal antibodies, and fragments thereof, that bind to the chemokine Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES, CCL5), thereby modulating the interaction between RANTES and one of more of its receptors, such as, e.g., CCR1, CCR3, CCR4 and CCR5, and/or modulating the biological activities of RANTES. The invention also relates to the use of these or any anti-RANTES antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.Type: GrantFiled: August 11, 2011Date of Patent: March 18, 2014Assignee: NovImmune S.A.Inventors: Nicolas Fischer, Marie Kosco-Vilbois, Francois Mach
-
Patent number: 8668909Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.Type: GrantFiled: April 26, 2010Date of Patent: March 11, 2014Assignees: Baxter International Inc., Baxter Healthcare S.A., Dyax Corp.Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
-
Publication number: 20140065165Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.Type: ApplicationFiled: October 10, 2013Publication date: March 6, 2014Applicant: Crucell Holland B.V.Inventors: Ronald Vogels, Theodorus H. J. Kwaks
-
Publication number: 20140057796Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in breast cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in ER? breast cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the ER? breast cancer metastasis.Type: ApplicationFiled: October 5, 2011Publication date: February 27, 2014Applicants: Fundació Privada Institució Catalana De Recerca I Estudis Avançats, Fundació Privada Institut De Recerca BiomèdicaInventors: Roger Gomis, Maria Tarragona, Anna Arnal, Milica Pavlovic
-
Patent number: 8658169Abstract: The present invention relates to IL-25 antibody VH domains and target binding members (e.g., antibodies) that comprise such antibody VH domains and bind IL-25. The invention also relates to compositions comprising target binding members {e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease).Type: GrantFiled: September 30, 2009Date of Patent: February 25, 2014Assignee: Medical Research CouncilInventors: David John Matthews, Jillian Barlow, Andrew Neil James McKenzie
-
Publication number: 20140050723Abstract: Antibodies that penetrate cell nuclei and inhibit DNA repair or interfere with DNA metabolism are provided for treatment of cancer (both directly and by sensitizing cancer cells to DNA-damaging treatments) or inhibiting or preventing viral infection, proliferation or metabolism. The method involves treating cells with a composition containing cell-penetrating anti-DNA antibodies or derivatives thereof, alone or in combination with treatment that induces DNA damage such as DNA-damaging chemotherapy or radiation. The impact of the cell-penetrating anti-DNA antibodies or derivatives thereof is potentiated in cancer cells that are deficient in DNA repair, and the cell-penetrating anti-DNA antibodies or derivatives thereof are synthetically lethal to cancer cells with DNA repair deficiencies.Type: ApplicationFiled: April 2, 2012Publication date: February 20, 2014Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, YALE UNIVERSITYInventors: James E. Hansen, Peter M. Glazer, Richard H. Weisbart, Robert N. Nishimura, Grace Chan
-
Patent number: 8652843Abstract: Disclosed are DDR1 binding agents and methods of using the agents for treating diseases such as cancer. The disclosure provides antibodies that specifically bind to an extracellular domain of DDR1 and modulate DDR1 activity. The disclosure further provides methods of using agents that modulate the activity of DDRI, such as antibodies that specifically bind DDR1, to reduce the tumorigenicity of tumors comprising cancer stem cells by reducing the frequency or number of cancer stem cells in the tumor. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.Type: GrantFiled: August 12, 2009Date of Patent: February 18, 2014Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Edward Thein Htun Van Der Horst, Sanjeev H. Satyal
-
Publication number: 20140044720Abstract: Disclosed herein are human monoclonal antibodies that specifically bind both IGF-I and IGF-II with picomolar affinity and potently inhibit the IGF-IR signal transduction function. These antibodies are active in both an IgG and a scFv format. Bispecific forms of these antibodies are also disclosed. Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed herein. Also disclosed are pharmaceutical compositions including these antibodies. Methods are provided for treating a subject with cancer and for inhibiting phosphorylation of the insulin-like growth factor-I receptor. Methods are also provided for diagnosing cancer.Type: ApplicationFiled: April 11, 2012Publication date: February 13, 2014Applicant: Department of Health and Human ServiceInventors: Dimiter S. Dimitrov, Zhongyu Zhu, Qi Zhao
-
Publication number: 20140044714Abstract: Described herein is the identification of human monoclonal antibodies that bind GPC3 or heparan sulfate (HS) chains on GPC3 with high affinity. The antibodies described herein are capable of inhibiting HCC cell growth and migration. Provided are human monoclonal antibodies specific for GPC3 or HS chains on GPC3, including immunoglobulin molecules, such as IgG antibodies, as well as antibody fragments, such as single-domain VH antibodies or single chain variable fragments (scFv). Further provided are compositions including the antibodies that bind GPC3 or HS chains on GPC3, nucleic acid molecules encoding these antibodies, expression vectors comprising the nucleic acids, and isolated host cells that express the nucleic acids. Methods of treating cancer and/or inhibiting tumor growth or metastasis are also provided. Further provided are methods of detecting cancer in a subject and confirming a diagnosis of cancer in a subject.Type: ApplicationFiled: April 19, 2012Publication date: February 13, 2014Inventors: Mitchell Ho, Mingqian Feng, Wei Gao, Heungnam Kim, Dimiter S. Dimitrov
-
Patent number: 8648172Abstract: The present invention provides antibodies that simultaneously bind the ?- and ?-subunits of an intact MUC1 protein, and methods for making and using such antibodies.Type: GrantFiled: November 16, 2011Date of Patent: February 11, 2014Assignees: Biomodifying, LLC, Ramot at Tel Aviv University Ltd.Inventors: Daniel B. Rubinstein, Daniel H. Wreschner
-
Patent number: 8648182Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: GrantFiled: October 11, 2012Date of Patent: February 11, 2014Assignee: ZymoGenetics, Inc.Inventors: Cindy A. Sprecher, Scott R. Presnell, Zeren Gao, Theodore E. Whitmore, Joseph L. Kuijper, Mark F. Maurer
-
Patent number: 8647625Abstract: The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.Type: GrantFiled: July 26, 2005Date of Patent: February 11, 2014Assignee: Biogen Idec MA Inc.Inventors: Herman Van Vlijmen, Alexey Alexandrovic Lugovskoy, Karl J. M. Hanf
-
Patent number: 8648174Abstract: The present invention is directed to novel polypeptide, designated in the present application as “UCP4” (SEQ ID NO: 1), having homology to certain human uncoupling proteins (“UCPs”) and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention.Type: GrantFiled: November 8, 2012Date of Patent: February 11, 2014Assignee: Genentech, Inc.Inventors: Sean Adams, James Pan, Alan Zhong
-
Publication number: 20140037648Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that neutralize infection of both RSV, MPV and PVM. The invention also relates to nucleic acids that encode, immortalized B cells and cultured plasma cells that produce, and to polypeptides that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and polypeptides recognized by the antibodies of the invention in screening methods as well as in the diagnosis, treatment and prevention of RSV or MPV infection and RSV and MPV co-infection.Type: ApplicationFiled: March 14, 2013Publication date: February 6, 2014Applicant: HUMABS BIOMED SAInventor: HUMABS BIOMED SA
-
Patent number: 8642741Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human TNF-like ligand 1A (hTL1A) is provided. The human anti-hTL1A antibodies are useful in treating diseases or disorders associated with TL1A, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation.Type: GrantFiled: November 8, 2011Date of Patent: February 4, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Brendan J. Classon, Dimitris Skokos
-
Publication number: 20140030269Abstract: Human antibodies that bind to one or more strains Staphylococcus aureus strains, including methicillin resistant strains, are disclosed. Also disclosed are human recombinant polyclonal antibody compositions, and therapeutic methods for using the antibodies.Type: ApplicationFiled: July 26, 2013Publication date: January 30, 2014Applicant: Excelimmune, Inc.Inventor: Vincent W. Coljee
-
Publication number: 20140030273Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.Type: ApplicationFiled: February 1, 2012Publication date: January 30, 2014Applicant: GENMAB A/SInventors: Sandra Verploegen, Marije Overdijk, Riemke Van Dijkhuizen, Willem Karel Bleeker, Patrick Van Berkel, Paul Parren, Steen Lisby
-
Patent number: 8637641Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.Type: GrantFiled: July 29, 2011Date of Patent: January 28, 2014Assignee: Xencor, Inc.Inventors: Bassil I. Dahiyat, Gregory A. Lazar, Matthew J. Bernett
-
Patent number: 8637642Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.Type: GrantFiled: September 29, 2011Date of Patent: January 28, 2014Assignees: Seattle Genetics, Inc., Agensys, Inc.Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
-
Patent number: 8637643Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.Type: GrantFiled: January 15, 2013Date of Patent: January 28, 2014Assignee: UCB Pharma, S.A.Inventors: John Latham, David G. Winkler
-
Publication number: 20140017256Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.Type: ApplicationFiled: February 7, 2013Publication date: January 16, 2014Applicant: ABBVIE INC.Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
-
Patent number: 8628776Abstract: Described are human binding molecules specifically binding to enterococci and having killing activity against enterococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The molecules can be used in the diagnosis, prophylaxis, and/or treatment of a condition resulting from Enterococcus.Type: GrantFiled: July 16, 2012Date of Patent: January 14, 2014Assignee: Crucell Holland B.V.Inventors: Mark Throsby, Robert Arjen Kramer, Cornelis Adriaan De Kruif
-
Patent number: 8629250Abstract: The invention relates to purified, correctly folded hepcidin, antibodies that bind hepcidin, and methods of making and using such materials. Also provide are methods of treated hepcidin-related disorders.Type: GrantFiled: January 30, 2008Date of Patent: January 14, 2014Assignee: Amgen Inc.Inventors: Barbra Sasu, Mitsuru Haniu, Thomas Charles Boone, Xiao-juan Bi, Grace Ki Jeong Lee, Tara Arvedson, Aaron George Winters, Keegan Cooke, Jackie Z. Sheng
-
Publication number: 20140010810Abstract: This invention relates generally to the generation of antibodies, e.g., monoclonal antibodies including fully human monoclonal antibodies, that recognize Jagged 1 and/or Jagged 2, to antibodies, e.g., monoclonal antibodies including fully human antibodies that recognize Jagged 1 and/or Jagged 2, and nucleic acid molecules that encode antibodies, e.g., nucleic acid molecules that encode monoclonal antibodies including fully human cross-reactive antibodies that recognize both Jagged 1 and Jagged 2, and to methods of making the anti-Jagged antibodies and methods of using the anti-Jagged antibodies as therapeutics, prophylactics, and diagnostics. The invention also relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically bind to Jagged 1 and Jagged 2, and to methods of making and using these activatable anti-Jagged antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: June 21, 2013Publication date: January 9, 2014Inventors: James William West, Jason Gary Sagert, Paul H. Bessette, Henry Bernard Lowman, Nancy E. Stagliano, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
-
Publication number: 20140010811Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.Type: ApplicationFiled: June 27, 2013Publication date: January 9, 2014Applicant: University of Pittsburgh - Of The Commonwealth System of Higher EducationInventors: Soldano Ferrone, Xinhui Wang, Thomas P. Conrads, Elvira Favoino, Brian L. Hood
-
Publication number: 20140011982Abstract: The invention provides human scFv antibodies and monoclonal antibodies that neutralize influenza virus. Also provided are methods of treating and/or preventing a influenza related disease or disorder such bird flu The invention also provides methods of vaccinating a patient against influenza. Also provided are methods of diagnosing influenza-related diseases or disorders and methods of detecting the presence of a influenza in a sample.Type: ApplicationFiled: August 12, 2013Publication date: January 9, 2014Applicants: BURNHAM INSTITUTE FOR MEDICAL RESEARCH, DANA-FARBER CANCER INSTITUTE, INC.Inventors: Wayne A. Marasco, Jianhua Sui, Robert C. Liddington
-
Patent number: 8623368Abstract: The present invention relates to a human recombinant monoclonal antibody that specifically binds to human Vascular Cell Adhesion Molecule-1 (VCAM-1) to inhibit adhesion between leukocytes and activated endothelial cells and transmigration of leukocytes through the activated endothelial cells, and a prophylactic and therapeutic composition for inflammatory disease or cancer comprising the same. The human recombinant monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human endothelial cell, and effectively inhibits VCAM-1-mediated adhesion between leukocytes and activated endothelial cells and transmigration of leukocytes through the activated endothelial cells, thereby being used for the prevention and treatment of inflammatory disease such as asthma and arthritis, transplant rejection, cardiovascular disease, and cancer.Type: GrantFiled: October 22, 2010Date of Patent: January 7, 2014Assignee: Hanwha Chemical CorporationInventors: Jung Tae Lee, Kyung Duk Moon, Ji Yong Yoon, Byung Je Sung, Dong Heon Lee, Dong Eun Lee, Su Yeon Ryu, Hyun Bo Shim, Kyung Jae Kang
-
Patent number: 8623364Abstract: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.Type: GrantFiled: October 24, 2012Date of Patent: January 7, 2014Assignee: Morphotek, Inc.Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Jian Li, Qimin Chao, Eric Routhier, Wolfgang Ebel
-
Publication number: 20140005366Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.Type: ApplicationFiled: April 16, 2013Publication date: January 2, 2014Applicants: Cancer Research Technology Limited, Københavns UniversitetInventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
-
Patent number: 8618252Abstract: The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.Type: GrantFiled: December 13, 2010Date of Patent: December 31, 2013Assignee: Biogen Idec MA Inc.Inventors: Graham K. Farrington, Alexey Alexandrovich Lugovskoy, Werner Meier, John K. Eldredge, Ellen Garber
-
Patent number: 8614300Abstract: The invention pertains to nucleic acids encoding a mutT domain-containing polypeptide, including fragments and biologically functional variants thereof. The invention also pertains to therapeutics and diagnostics involving the foregoing polypeptide and nucleic acids and agents that bind the foregoing polypeptide and nucleic acids. The invention also pertains to the identification of a novel mutT domain in human TrpC7, a polypeptide previously described as a putative calcium ion channel. Accordingly, the invention also pertains to methods and compositions for identifying agents useful in modulating mutT domain-mediated calcium or other ion transport in cells expressing a polypeptide comprising a mutT domain and a calcium or other ion channel.Type: GrantFiled: March 9, 2012Date of Patent: December 24, 2013Assignee: Beth Israel Deconess Medical Center, Inc.Inventor: Andrew M. Scharenberg
-
Patent number: 8609820Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.Type: GrantFiled: October 26, 2012Date of Patent: December 17, 2013Assignee: Neotope Biosciences LimitedInventors: Jose Saldanha, Tarlochan S. Nijjar
-
Patent number: 8609816Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to O8E with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer.Type: GrantFiled: December 8, 2006Date of Patent: December 17, 2013Assignee: Medarex, L.L.C.Inventors: Alan J. Korman, Mark J. Selby, Li-Sheng Lu, Alison Witte, Haichun Huang